ReviewBiosensors & bioelectronics2020
CRISPR/cas systems redefine nucleic acid detection: Principles and methods.
Review in Biosensors & bioelectronics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 251 citations in OpenAlex.
- CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges.Frontiers in microbiology · 2026Pooled it
- SARS-CoV-2 Point-of-Care Testing Modalities: Integrating Molecular, Immunological, Biosensor, and AI Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- AlphaFold3-guided tracrRNA redesign yields small monomeric Cas12f RNPs.Nucleic acids research · 2026Article
- Programmable hooded DNA switches for conditional control of CRISPR/Cas12a in multiplexed biosensing.Journal of nanobiotechnology · 2026Article
- Red and blue microspheres based immunoassay combined with RPA and Cas12a for dual-detection of nucleic acid from foodborne pathogens.Mikrochimica acta · 2026Article
- Emerging Argonaute-based food safety detection: from amplification to amplification-free manner.Frontiers in microbiology · 2026Review
- CRISPR/Cas Technology for the Diagnosis of Animal Infectious Diseases.Microorganisms · 2025Review
- Design Principles of Nanosensors for Multiplex Detection of Contaminants in Food.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- CRISPR-Cas13a as a next-generation tool for rapid and precise plant RNA virus diagnostics.Plant methods · 2025Review
- Ultra-sensitive biosensor detection of microRNA based on the CRISPR/Cas12a system and exonuclease-assisted target recycling signal amplification.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Article
- Dual DNA recycling amplification-assisted CRISPR/Cas12a cleavage for dual-channel ratiometric fluorescence biosensing of kanamycin antibiotic.Analytical and bioanalytical chemistry · 2025Article
- Article
- Machine learning in point-of-care testing: innovations, challenges, and opportunities.Nature communications · 2025Review
- Quencher-free CRISPR-based molecular detection using an amphiphilic DNA fluorescence probe.Biosensors & bioelectronics · 2025Article
- Rapid Genotyping ofBiomolecules · 2025Article
- New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14.Heliyon · 2025Review
- Amplification-free sensitive detection of Staphylococcus aureus by spherical nucleic acid triggered CRISPR/Cas12a and Poly T-Cu reporter.Mikrochimica acta · 2025Article
- CRISPR/Cas-Based Nanobiosensor Using Plasmonic Nanomaterials to Detect Disease Biomarkers.Biochip journal · 2025Review
- CRISPR-Cas9-based electrochemical biosensor for the detection ofADMET & DMPK · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methods that enable rapid, sensitive and specific analyses of nucleic acid sequences have positive effects on precise disease diagnostics and effective clinical treatments by providing direct insight into clinically relevant genetic information. Thus far, many CRISPR/Cas systems have been repurposed for diagnostic functions and are revolutionizing the accessibility of robust diagnostic tools due to their high flexibility, sensitivity and specificity. As RNA-guided targeted recognition effectors, Cas9 variants have been utilized for a variety of diagnostic applications, including biosensing assays, imaging assays and target enrichment for next-generation sequencing (NGS), thereby enabling the development of flexible and cost-effective tests. In addition, the ensuing discovery of Cas proteins (Cas12 and Cas13) with collateral cleavage activities has facilitated the development of numerous diagnostic tools for rapid and portable detection, and these tools have great potential for point-of-care settings. However, representative reviews proposed on this topic are mainly confined to classical biosensing applications; thus, a comprehensive and systematic description of this fast-developing field is required. In this review, based on the detection principle, we provide a detailed classification and comprehensive discussion of recent works that harness these CRISPR-based diagnostic tools from a new perspective. Furthermore, current challenges and future perspectives of CRISPR-based diagnostics are outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.